Clinical Trials Directory

Trials / Completed

CompletedNCT00217568

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with carboplatin works in treating patients with relapsed stage III or stage IV ovarian epithelial or primary peritoneal cavity cancer.

Detailed description

OBJECTIVES: * Determine the toxicity of docetaxel and carboplatin in patients with platinum-sensitive stage III or IV ovarian epithelial or primary peritoneal cavity cancer in first relapse. * Determine the response rates (complete and partial response) in patients treated with this regimen. * Determine relapse rates and event-free survival and overall survival rates in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2 . Treatment repeats every 21 days for up to 6 courses. After completion of study treatment, patients are followed at 3 weeks, every 3 months for 2 years, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 4-5 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALpegfilgrastim
DRUGcarboplatin
DRUGdocetaxel

Timeline

Start date
2005-05-01
Primary completion
2006-03-01
First posted
2005-09-22
Last updated
2010-09-21

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00217568. Inclusion in this directory is not an endorsement.